A patient advocacy group in the UK is calling for changes to the decade-old meningitis vaccination programme, after an ...

Roche has ramped up its investment in NVIDIA's AI chips, launching an upscaled hybrid-cloud AI factory that it believes is ...

NYSE-listed Alto Neuroscience has raised $120 million in a private placement that will be used to advance its recently acquired candidate for treatment-resistant depression (TRD) into a pivotal trials ...

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening its label, while it investigates a potential safety issue. In a financial regulatory filing, ...

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...

Rentschler taps biopharma vet to lead ops. Rentschler Biopharma, the German CDMO with offices in Massachusetts and Stevenage, ...

In order to discuss this topic further, pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata ...

A federal judge has pushed back against attempts by HHS Secretary Robert F Kennedy Jr to overhaul immunisation policy in the US, blocking changes to the recommended schedule as well as his ...

The US regulator has cleared its Arexvy RSV shot for adults in that age group who are at increased ​risk of lower respiratory ...

The analysis – reported at the European Association of Urology (EAU) annual congress in London, UK – shows that it is "no longer rational to reject prostate cancer screening on one hand while ...

Pharmaceutical organisations rarely struggle to write strategy. They struggle to protect it. Global brand teams define ambition precisely. Segmentation models are refined. Launch plans are ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.